Clinical outcomes of post-surgery osteoporosis treatment in elderly intertrochanteric fracture patients: a prospective study

Authors

  • Ishaan Siwach Central Institute of Orthopaedics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
  • Loveneesh G. Krishna Central Institute of Orthopaedics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
  • Jatin Talwar Central Institute of Orthopaedics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
  • Ashish Rustagi Central Institute of Orthopaedics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
  • Navdeep S. Keer Central Institute of Orthopaedics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20243124

Keywords:

Fragility fractures, Osteoporosis, Geriatric fractures, Intertrochanteric femur, Bisphosphonates, Zoledronate

Abstract

Background: This study aims to evaluate the clinical and functional outcomes of administering zoledronic acid in elderly patients undergoing surgical management of hip fractures. The goal is to assess the impact on mortality, postoperative complications, and functional recovery as measured by the modified Harris hip score.

Methods: A prospective study was conducted over 18 months at a tertiary care center in New Delhi, India, involving 42 patients aged 60 and above with intertrochanteric femur fractures. Patients received surgical fixation and standard postoperative care. Zoledronic acid (5 mg) was administered intravenously three months post-surgery. Data on demographics, injury-to-surgery interval, fracture type, DEXA score, and functional outcomes were collected at follow-ups of 6 weeks, 3 months, 6 months, and 12 months.

Results: The mean age of participants was 72.67 years. Zoledronic acid administration was associated with a 9.5% mortality rate. Functional outcomes, measured by the modified Harris hip score, significantly improved from a mean of 42.14 at 6 weeks to 77.68 at 12 months (p<0.001). Younger patients (<70 years) had significantly better scores at 3 months compared to older patients (>80 years). However, no significant differences were observed at 6 and 12 months. The mean modified Harris hip scores did not differ significantly between patients with osteopenia and osteoporosis at any time point. Additionally, the type of surgical fixation (intramedullary versus extramedullary) showed no significant impact on functional outcomes.

Conclusions: Zoledronic acid administration in elderly hip fracture patients may reduce mortality and enhance functional recovery. The study supports its use in postoperative care to improve outcomes, although larger, randomized controlled studies are needed to confirm these findings. The results suggest that zoledronic acid can be an effective adjunct therapy in managing osteoporosis-related hip fractures in the geriatric population.

References

Yadav L, Tewari A, Jain A, Essue B, Peiris D, Woodward M, et al. Protocol-based management of older adults with hip fractures in Delhi, India: a feasibility study. Pilot Feasibility Stud. 2016;2(1):1-6.

Canale ST. Campbell’s operative orthopaedics. St. Louis: Mosby. Manole. 10th edition. 2003;50:2677.

Lu Y, Uppal HS. Hip fractures: relevant anatomy, classification, and biomechanics of fracture and fixation. Geriatr Orthop Surg Rehabil. 2019;10:2151459319859139.

Porter JL, Varacallo M, Castano M. Osteoporosis (Nursing). StatPearls Publishing. 2022.

Green JR. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organometal Chem. 2005;690(10):2439-48.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22.

Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46.

Colón‐Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Mineral Res. 2010;25(1):91-7.

Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated γδ T cells: role of CD86 and inflammatory cytokines. J Immunol. 2005;174(1):252-60.

Karakus O, Ozdemir G, Karaca S, Cetin M, Saygi B. The relationship between the type of unstable intertrochanteric femur fracture and mobility in the elderly. J Orthop Surg Res. 2018;13(1):207.

Sharma A, Sethi A, Sharma S. Treatment of stable intertrochanteric fractures of the femur with proximal femoral nail versus dynamic hip screw: a comparative study. Rev Bras Ortop. 2018;53(4):477-81.

Jeong GK, Gruson KI, Egol KA, Aharonoff GB, Karp AH, Zuckerman JD, et al. Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents. Am J Orthop. 2007;36(3):135.

Rempel AN, Rigassio Radler DL, Zelig RS. Effects of the use of oral nutrition supplements on clinical outcomes among patients who have undergone surgery for hip fracture: A literature review. Nutr Clin Pract. 2023;38(4):775-89.

Gupta R, Vashist D, Gupta P, Soni A. Predictors of 1-year Mortality After Hip Fracture Surgery in Patients with Age 50 years and Above: An Indian Experience. Indian J Orthop. 2021;55(2):395-401.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid in reducing clinical fructure and mortality after hip fracture. N Engl J Med. 2007;357:nihpa40967.

Cengiz Ö, Polat G, Karademir G, Tunç OD, Erdil M, Tuncay İ, et al. Effects of zoledronate on mortality and morbidity after surgical treatment of hip fractures. Adv Orthop. 2016;2016:3703482.

Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteopor Int. 2011;22:983-91.

Gulia A, Das SP, Sondur S, Rajendran P, Mohanty A, Prakash V, et al. Zoledronic Acid Does Not Retard Bone Union: A Randomized Controlled Trial in Fragility Intertrochanteric Femur Fractures. Cureus. 2023;15(1).

Taoka T, Ohmori T, Kanazawa T, Toda K, Ishihara T, Ito Y. Delayed surgery after hip fracture affects the incidence of venous thromboembolism. J Orthop Surg Res. 2023;18(1):630.

Kotian P, Boloor A, Sreenivasan S. Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. J Clin Diagnost Res. 2016;10(1):OC04.

Downloads

Published

2024-10-25

Issue

Section

Original Research Articles